DiaMedica (DMAC) CEO Pauls Dietrich John Receives 60,200 RSUs

What Happened Pauls Dietrich John, President & CEO and Director of DiaMedica Therapeutics Inc. (DMAC), received a grant of 60,200 restricted stock units (RSUs) on 2026-08-10. The RSUs were granted at $0.00 per share (total reported value $0) and are an award rather than a purchase or sale.

Key Details

• Transaction date: 2026-08-10 (Form filed 2026-08-12).
• Transaction type/code: Award/Grant (A).
• Shares/units granted: 60,200 RSUs at $0.00 (total reported value $0).
• Vesting: RSUs vest in four equal installments on each anniversary of the grant date, subject to continued service (see footnote F1).
• Holdings note: Filing references 1,749 voting common shares issuable upon settlement of deferred share units under the company’s Deferred Share Unit Plan (footnote F2).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Timeliness: Form 4 was filed two days after the transaction date; the filing does not indicate a late report.

Context RSUs are conditional awards that convert to common shares only if vesting and service conditions are met; they are typically used for executive compensation/retention. This grant is an award (neutral in market-sentiment terms) rather than an immediate purchase or sale and does not represent immediate cash proceeds or a taxable event until vesting/settlement (tax implications depend on when shares are delivered).